

**GLUCOCORTICOIDS, ORAL PRIOR AUTHORIZATION FORM** (form effective 1/5/2026)

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

OR Prior authorization may be completed at <https://www.covermymeds.com/main/prior-authorization-forms/>

Prior authorization guidelines for **Glucocorticoids, Oral** and **Quantity Limits/Daily Dose Limits** are available on the PA Health & Wellness website at <https://www.pahealthwellness.com/providers/pharmacy.html>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	Total pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Member name:		City/state/zip:	
Member ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	
Dose/directions:	Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):	DX code (<i>required</i>):	

Complete all sections that apply to the member and this request.**Check all that apply and submit documentation for each item.****1. For a NON-PREFERRED Glucocorticoid, Oral:**

- ☐ Tried and failed or has a contraindication or an intolerance to the preferred Glucocorticoids, Oral that are approved or medically accepted for the member's diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)

2. For treatment of EOSINOPHILIC ESOPHAGITIS (EOE):

- ☐ Tried and failed or has a contraindication or an intolerance to inhaled fluticasone propionate

3. For treatment of PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IgAN):

- ☐ Has a diagnosis of IgAN that is confirmed by a kidney biopsy
- ☐ Is prescribed the requested drug by or in consultation with a nephrologist
- ☐ Has 3 or more of the following features indicating the member is at very high risk for progressive disease or already has progressive disease despite at least 3 to 6 months of maximally tolerated doses of an ACE inhibitor or ARB based on current consensus guidelines:
- ☐ Persistent proteinuria ≥ 1 g/day on at least 2 separate tests

- ☐ Persistent moderate microscopic hematuria/hemoglobinuria (arbitrarily defined as 1+ or greater on urine dipstick or >10 RBCs/hpf on at least two separate tests, in the absence of another possible cause)
- ☐ Progressive decline in kidney function (eg, documented or inferred by an eGFR 3 mL/min/1.73 m² per year) considered to be due to active IgAN
- ☐ Evidence of one or more active lesions on recent kidney biopsy (eg, Oxford classification M1, E1, or C1 or C2 scores [particularly crescents involving >10 percent of glomeruli]) or an S1 lesion with podocyte hypertrophy
- ☐ Has an eGFR \geq 35 mL/min/1.73 m²

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 844-205-3386

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)